QuidelOrtho Corp.

As of October 10, 2025, QuidelOrtho Corp. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals on weekly and monthly charts, and has underperformed the S&P 500 with a year-to-date return of -40.94%.

As of October 10, 2025, QuidelOrtho Corp. is in a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearish signals, while it has underperformed the S&P 500 significantly, showing a year-to-date return of -40.81% compared to the S&P 500's 11.41%.

As of October 10, 2025, QuidelOrtho Corp. is in a mildly bearish trend, with daily indicators showing bearish momentum despite some mildly bullish signals on longer time frames, and it has underperformed the S&P 500 with a year-to-date return of -40.81%.

As of October 3, 2025, QuidelOrtho Corp. shows a mildly bullish technical trend, supported by positive MACD and KST indicators, but has significantly underperformed the S&P 500 with a year-to-date return of -33.56%.

As of October 3, 2025, QuidelOrtho Corp. shows a mildly bullish trend supported by several indicators, despite underperforming the S&P 500 significantly over the past year and three years, with caution advised due to mixed signals in moving averages and Bollinger Bands.

As of September 19, 2025, QuidelOrtho Corp. shows a mildly bearish trend, with mixed technical indicators and significant underperformance against the S&P 500, including a year-to-date return of -36.12%.

As of September 19, 2025, QuidelOrtho Corp. shows a mildly bearish technical trend, primarily indicated by daily moving averages and monthly Bollinger Bands, with significant underperformance compared to the S&P 500.

As of August 22, 2025, QuidelOrtho Corp. is in a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -33.24% compared to the S&P's 12.22%.

As of February 13, 2024, QuidelOrtho Corp. is considered risky and overvalued due to a negative P/E ratio of -24.49, low ROE of -2.58%, and poor stock performance, with a year-to-date decline of 37.93% compared to a 2.44% gain for the S&P 500.

As of May 27, 2025, the market trend is mildly bearish, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and KST.

As of March 2022, the management team of QuidelOrtho Corp. includes Dr. Kenneth Buechler (Independent Chairman), Mr. Douglas Bryant (President and CEO), and several independent directors: Ms. Ann Rhoads, Mr. Edward Michael, Ms. Kathy Ordonez, Dr. Mary Polan, and Mr. Charles Slacik, reflecting a diverse leadership structure.

QuidelOrtho Corp. develops, manufactures, and markets diagnostic testing solutions in the Pharmaceuticals & Biotechnology industry, with a recent net sales of $694 million and a market cap of approximately $1.9 billion. The company reported a net profit of -$13 million for the most recent quarter.

As of Jun 18, QuidelOrtho Corp. has a market capitalization of $1.90 billion, with net sales of $2.77 billion and a net profit of -$333.70 million over the last four quarters. Shareholder's funds are $2.98 billion, and total assets amount to $6.97 billion.